CoChat

Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors

Open access
Sacco, Joseph J., Kenyani, Jenna, Butt, Zohra, Carter, Rachel, Chew, Hui Yi, Cheeseman, Liam P., Darling, Sarah, Denny, Michael, Urbé, Sylvie, Clague, Michael J., Coulson, Judy M. · 2015 · Oncotarget
Cited by 59

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

// Joseph J. Sacco 1 , Jenna Kenyani 1 , Zohra Butt 1 , Rachel Carter 1 , Hui Yi Chew 1, 2 , Liam P. Cheeseman 1, 3 , Sarah Darling 1 , Michael Denny 1 , Sylvie Urbé 1 , Michael J. Clague 1 , Judy M. Coulson 1 1 Cellular & Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK 2 Current address: Cancer Stem Cell Biology, Agency for Science Technology and Research, Genome Institute of Singapore, Singapore 3 Current address: MRC Laboratory of Molecular Biology, Cambridge, UK Correspondence to: Judy M. Coulson, e-mail: j.m.coulson@liv.ac.uk Keywords: histone deacetylase 2, BRCA1-associated protein 1, MPM, vorinostat, stratified medicine Received: October 31, 2014 Accepted: April 10, 2015 Published: April 24, 2015 ABSTRACT Histone deacetylases are important targets for cancer therapeutics, but their regulation is poorly understood. Our data show coordinated transcription of HDAC1 and HDAC2 in lung cancer cell lines, but suggest HDAC2 protein expression is cell-context specific. Through an unbiased siRNA screen we found that BRCA1-associated protein 1 (BAP1) regulates their expression, with HDAC2 reduced and HDAC1 increased in BAP1 depleted cells. BAP1 loss-of-function is increasingly reported in cancers including thoracic malignancies, with frequent mutation in malignant pleural mesothelioma. Endogenous HDAC2 directly correlates with BAP1 across a panel of lung cancer cell lines, and is downregulated in mesothelioma cell lines with genetic BAP1 inactivation. We find that BAP1 regulates HDAC2 by increasing transcript abundance, rather than opposing its ubiquitylation. Importantly, although total cellular HDAC activity is unaffected by transient depletion of HDAC2 or of BAP1 due to HDAC1 compensation, this isoenzyme imbalance sensitizes MSTO-211H cells to HDAC inhibitors. However, other established mesothelioma cell lines with low endogenous HDAC2 have adapted to become more resistant to HDAC inhibition. Our work establishes a mechanism by which BAP1 loss alters sensitivity of cancer cells to HDAC inhibitors. Assessment of BAP1 and HDAC expression may ultimately help identify patients likely to respond to HDAC inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.3765

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 50

  1. Mann, 2009, Lysine acetylation targets protein complexes and co-regulates major cellular functions, Science, 325, 834, 10.1126/science.1175371 · DOI · Paper page
  2. Chabner, 2009, Histone deacetylase inhibitors in cancer therapy, J Clin Oncol, 27, 5459, 10.1200/JCO.2009.22.1291 · DOI · Paper page
  3. Seiser, 2014, Transcription and beyond: the role of mammalian class I lysine deacetylases, Chromosoma, 123, 67, 10.1007/s00412-013-0441-x · DOI
  4. Chiocca, 2007, Role for histone deacetylase 1 in human tumor cell proliferation, Mol Cell Biol, 27, 4784, 10.1128/MCB.00494-07 · DOI · Paper page
  5. Rahman, 2009, Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke, Am J Respir Cell Mol Biol, 40, 464, 10.1165/rcmb.2008-0255OC · DOI · Paper page
  6. Chiocca, 2011, Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2, J Biomed Biotechnol, 2011, 690848
  7. Robson, 2005, Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation, Nucleic Acids Res, 33, 13, 10.1093/nar/gki141 · DOI · Paper page
  8. Seol, 2009, Chfr is linked to tumour metastasis through the downregulation of HDAC1, Nat Cell Biol, 11, 295, 10.1038/ncb1837 · DOI
  9. Zhong, 2011, Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2, Genes Dev, 25, 2610, 10.1101/gad.170605.111 · DOI
  10. Marks, 2007, Discovery and development of SAHA as an anticancer agent, Oncogene, 26, 1351, 10.1038/sj.onc.1210204 · DOI · Paper page
  11. Natoli, 2013, Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies, Cancers, 5, 919, 10.3390/cancers5030919 · DOI
  12. Wright, 2012, Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer, Pharmaceutical patent analyst, 1, 207, 10.4155/ppa.12.21 · DOI
  13. Coulson, 2014, The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells, Oncogene, 33, 4265, 10.1038/onc.2013.512 · DOI · Paper page
  14. Coulson, 2013, The deubiquitylase USP15 stabilizes newly synthesized REST and rescues its expression at mitotic exit, Cell Cycle, 12, 1964, 10.4161/cc.25035 · DOI
  15. Hasegawa, 2012, Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma, Cancer Sci, 103, 868, 10.1111/j.1349-7006.2012.02223.x · DOI · Paper page
  16. Friedberg, 2012, BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs, J Transl Med, 10, 179, 10.1186/1479-5876-10-179 · DOI · Paper page
  17. Therrien, 2014, Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O, Mol Cell, 54, 392, 10.1016/j.molcel.2014.03.002 · DOI · Paper page
  18. Schultz, 1998, BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression, Oncogene, 16, 1097, 10.1038/sj.onc.1201861 · DOI · Paper page
  19. Goldstein, 2011, Germline BAP1 mutations and tumor susceptibility, Nat Genet, 43, 925, 10.1038/ng.956 · DOI
  20. Pirun, 2011, Germline mutations in BAP1 predispose to melanocytic tumors, Nat Genet, 43, 1018, 10.1038/ng.910 · DOI · Paper page
  21. Bowcock, 2010, Frequent mutation of BAP1 in metastasizing uveal melanomas, Science, 330, 1410, 10.1126/science.1194472 · DOI · Paper page
  22. Zhao, 2011, Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma, Nat Genet, 44, 17
  23. Davidorf, 2011, Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers, J Med Genet, 48, 856, 10.1136/jmedgenet-2011-100156 · DOI · Paper page
  24. Gyapay, 2013, Germline BAP1 mutations predispose to renal cell carcinomas, Am J Hum Genet, 92, 974, 10.1016/j.ajhg.2013.04.012 · DOI · Paper page
  25. Scolyer, 2013, Tumours associated with BAP1 mutations, Pathology, 45, 116
  26. Shen, 2012, BAP1 is a good prognostic factor in advanced non-small cell lung cancer, Clin Invest Med, 35, E182, 10.25011/cim.v35i4.17146 · DOI
  27. Kang, 2013, Prognostic significance of BRCA1-associated protein 1 in colorectal cancer, Med Oncol, 30, 541, 10.1007/s12032-013-0541-8 · DOI
  28. Murali, 2013, BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma, Pathology, 45, 651
  29. Lotan, 2014, BAP1 Immunohistochemistry Predicts Outcomes in a Multi-Institutional Cohort with Clear Cell Renal Cell Carcinoma, J Urol, 191, 603, 10.1016/j.juro.2013.09.041 · DOI
  30. Parker, 2014, Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma, Cancer, 120, 1059, 10.1002/cncr.28521 · DOI · Paper page
  31. Popper, 2014, BAP1 protein is a progression factor in malignant pleural mesothelioma, Pathol Oncol Res, 20, 145, 10.1007/s12253-013-9677-2 · DOI
  32. Coupland, 2014, Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing, Br J Cancer, 111, 1373, 10.1038/bjc.2014.417 · DOI · Paper page
  33. Muller, 2010, Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB, Nature, 465, 243, 10.1038/nature08966 · DOI · Paper page
  34. Wilson, 2009, Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1, Mol Cell Biol, 29, 2181, 10.1128/MCB.01517-08 · DOI · Paper page
  35. Harper, 2009, Defining the human deubiquitinating enzyme interaction landscape, Cell, 138, 389, 10.1016/j.cell.2009.04.042 · DOI · Paper page
  36. Katavolos, 2012, Loss of the tumor suppressor BAP1 causes myeloid transformation, Science, 337, 1541, 10.1126/science.1221711 · DOI · Paper page
  37. Brosch, 2013, Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis, EMBO J, 32, 3176, 10.1038/emboj.2013.243 · DOI · Paper page
  38. Seiser, 2011, Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis, Cell Cycle, 10, 406, 10.4161/cc.10.3.14712 · DOI · Paper page
  39. Ladanyi, 2013, Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations, J Thorac Oncol., 8, 1430, 10.1097/JTO.0b013e31829e7ef9 · DOI · Paper page
  40. Testa, 2002, The pathogenesis of mesothelioma, Semin Oncol, 29, 2, 10.1053/sonc.2002.30227 · DOI · Paper page
  41. Harbour, 2013, BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma, BMC Cancer, 13, 371, 10.1186/1471-2407-13-371 · DOI
  42. Petel, 2014, Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition, Clin Cancer Res, 20, 1323, 10.1158/1078-0432.CCR-13-2429 · DOI · Paper page
  43. Santoro, 2009, Future developments in the management of malignant pleural mesothelioma, Expert Rev Anticancer Ther, 9, 453, 10.1586/era.09.2 · DOI
  44. Smith, 2005, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 434, 917, 10.1038/nature03445 · DOI · Paper page
  45. Di Noia, 2014, Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair, Proc Natl Acad Sci U S A, 111, 285, 10.1073/pnas.1309085110 · DOI · Paper page
  46. Olgac, 2005, Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer, J Clin Oncol, 23, 3923, 10.1200/JCO.2005.14.167 · DOI · Paper page
  47. Krug, 2012, Novel therapies in phase II and III trials for malignant pleural mesothelioma, J Natl Compr Canc Netw, 10, 42, 10.6004/jnccn.2012.0007 · DOI
  48. Yang, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699 · DOI · Paper page
  49. Harbour, 2012, Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma, Clin Cancer Res, 18, 408, 10.1158/1078-0432.CCR-11-0946 · DOI · Paper page
  50. Coulson, 2009, SCG3 transcript in peripheral blood is a prognostic biomarker for REST-deficient small cell lung cancer, Clin Cancer Res, 15, 274, 10.1158/1078-0432.CCR-08-1163 · DOI

Cited by

See all 59

Metadata

Authors
Sacco, J. J., Kenyani, J., Butt, Z., Carter, R., Chew, H. Y., Cheeseman, L. P., Darling, S., Denny, M., Urbé, S., Clague, M. J., & Coulson, J. M.
Venue
Oncotarget
Published
2015-04-24
Volume
6
Issue
15
Pages
13757-13771
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1961955832
Cited by
59
References
10
FWCI
2.06
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.